Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical outcomes associated with COVID-19 vaccination: a cohort study in Lombardy, Italy

Table 3 Harm-benefit profile of the Moderna and Pfizer-BioNTech vaccines by sex and age category

Individuals receiving the Moderna vaccine
Men			Women
Number Needed to Harm	Number Needed to Treat	Age categories	Number Needed to Harm	Number Needed to Treat
30,252	21,876	12 to 15 years	–	33,621
6747	10,317	16 to 19 years	34,997	7861
11,086	7060	20 to 29 years	41,819	4621
47,910	1085	≥ 30 years	210,530	1527

Individuals receiving the Pfizer-BioNTech vaccine
Men			Women
Number Needed to Harm	Number Needed to Treat	Age categories	Number Needed to Harm	Number Needed to Treat
21,557	17,800	12 to 15 years	–	21,148
34,095	13,069	16 to 19 years	122,747	10,317
48,036	6660	20 to 29 years	142,873	7060
239,663	1105	≥ 30 years	370,479	1085

The restricted cohort of 7,907,765 vaccine recipients who experienced at least one vaccine administration were included in this analysis

ISSN: 1471-2334